PDF
ePub
Citation
Print
Abstract
Objectives
Schizophrenia patients are known to be more prone to metabolic disease than normal people. This study aimed to identify the changes in metabolic parameters of schizophrenia patients using atypical antipsychotic drugs for 1 year.
Methods
A total of 200 schizophrenia patients were recruited and categorized into the aripiprazole-treatment group and control group taking 5 atypical antipsychotic drugs. Comparative analysis were between groups. The prescriptions of psychotropic drugs were collected by a review of medical records. Blood was collected after fasting for 12 hours at the starting point of treatment and the 12th month, and patient medical records were evaluated for basici nformation and treatment history. Physical measurement, the prevalence of metabolic syndrome and metabolic parameters were studied using ATP-III diagnostic criteria.
Results
From the study, the aripiprazole-treatment group had a mean weight increase of 0.6 kg and the control group had a mean weight increase of 6.5 kg at the 1 year followup, showing a significant difference between the two groups. There were also significant differences between the two groups in waist size, systolic and diastolic blood pressure, fasting blood sugar, total cholesterol, triglyceride, HDL-choleseterol and prolactin level. Along with meaningful improvement of the symptoms, aripiprazole-treatment group showed less effect on in abdominal obesity, diabetes, blood pressure, cholesterol and prolactin than other atypical antipsychotic drugs.
REFERENCES
1). Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004; 161:1334–1349.
2). Haupt DW. Different metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol. 2006; 16:149–155.
3). Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. Abnormalities in glucose regulation during anti-psychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002; 59:337–345.
4). Faulkner G, Cohn T, Remington G, Irving H. Body mass index, waist circumference and quality of life in individuals with schizophrenia. Schizophr Res. 2007; 90:174–178.
5). Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol. 2002; 22:244–251.
6). Lambert M, Conus P, Eide P, Mass R, Karow A, Moritz S, et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry. 2004; 19:415–422.
7). Baptista T. Body weight gain induced by antipsychotic drugs; mechanisms and management. Acta Psychiatr Scand. 1999; 100:3–16.
8). Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent develop-ments and current perspectives. J Clin Psychopharmacol. 2007; 27:639–661.
9). Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004; 70:1–17.
10). McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trialsof Intervention Effectiveness(CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005; 80:19–32.
11). Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med. 2005; 118:15–22.
12). L'Italien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry. 2007; 68:1510–1516.
13). Lambert M, Conus P, Eide P, Mass R, Karow A, Moritz S, et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry. 2004; 19:415–422.
14). American Psychiatric Association: The diagnostic and statistical manual of mental disorder. 4th ed, Washington DC, American Psychiatric Press. 1994.
15). Ma GF, Raivio N, Sabria J, Ortiz J. Agonist and antagonist effects of aripiprazole on D2-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic tone. Int J Neuropsychopharmacol. 2014; 18:1–9.
16). Takahata K, Ito H, Takano H, Arakawa R, Fujiwara H, Kimura Y, et al. Striatal and extrastriatal dopamine D2 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [11 C]raclopride and [11 C]FLB457. Psychopharmacology (Berl). 2012; 222:165–172.
17). Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adult (Adult Treatment Panel III). JAMA. 2001; 285:2486–2497.
18). The asia-pacific perspective: redefining obesity and its treatment. Sid-ney, Australia, Health Communications Australia Pty Limit. 2000.
19). Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004; 70:1–17.
20). McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al. A comprehensive of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004; 65(suppl 18):47–56.
21). Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009; 65:510–517.
22). Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001; 62:22–31.
23). Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, et al. Avec le soutien institutionnel du laboratoire Lilly. Drawing up guidelines for the attendance of physical health of patients with severe mental illness. Encephale. 2009; 35:330–339.
24). Ko YK, Soh MA, Kang SH, Lee JI. The prevalence of metabolic syndrome in schizophrenic patients using antipsychotics. Clin Psychopharmacol Neurosci. 2013; 11:80–88.
25). Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull. 2002; 36:143–164.
26). Hanssens L, L'ltalien G, Loze JY, Marcus RN, Pans M, Kerselaers W. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry. 2008; 8:95.
Table 1.
Characteristics of demographic and biochemical parametric markers of total subjects
Table 2.
The change of biochemical metabolic parameters for 52 weeks
Table 3.
The change of prevalence of metabolic syndrome and markers in schizophrenic patients for 52 weeks
1) Abdominal obesity : male ≥90 cm, female ≥80 cm, 2) FBS ≥100 mg/dL or current ongoing treatment, 3) BP : systolic ≥130 mmHg or diastolic ≥85 mmHg or current ongoing treatment, 4) HDL-C : male ＜40 mg/dL, female ＜50 mg/dL or current ongoing treatment, 5) TG ≥150 mg/dL or current ongoing treatment. ATPIIIa : Adult Treatment Panel III
XML Download